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AutoregulationThe tumor suppressor protein programmed cell death 4 (Pdcd4) is a highly conserved RNA-binding protein that
inhibits the translation of speciﬁc mRNAs. Here, we have identiﬁed the homeobox-interacting protein kinase-2
(Hipk2) mRNA as a novel translational target of Pdcd4. Unlikemost other protein kinases Hipk2 is constitutively
active after being synthesized by the ribosomeand its expression and activity are thought to bemainly controlled
by modulation of the half-life of the kinase. Our work provides the ﬁrst evidence that Hipk2 expression is also
controlled on the level of translation. We show that Hipk2 stimulates the translation of its own mRNA and that
Pdcd4 suppresses the translation of Hipk2 mRNA by interfering with this auto-regulatory feedback mechanism.
We also show that the translation of the related kinase Hipk1 is controlled by a similar feedback loop and that
Hipk2 also stimulates the translation of Hipk1 mRNA. Taken together, our work describes a novel mechanism
of translational suppression by Pdcd4 and shows for the ﬁrst time that Hipk2 controls its own synthesis by an
auto-regulatory feedbackmechanism. Furthermore, the effect of Hipk2 on the translation of Hipk1 RNA suggests
that Hipk2 and Pdcd4 can act in similar manner to control the translation of other mRNAs.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Pdcd4 (Programmed cell death 4) was initially identiﬁed as a gene
whose expression is increased during apoptosis [1] andwas subsequent-
ly shown to function as a tumor suppressor in an in-vitro keratinocyte
model of tumor promotion [2] and an in-vivomodel of skin carcinogen-
esis [3]. Decreased expression of Pdcd4 has now been implicated in the
development of several human cancers, including lung, colon, liver and
breast cancer and glioblastoma [4–8], further supporting its role as a
tumor suppressor gene. In many cases, suppression of Pdcd4 expression
is due to increased expression of the oncogenic micro-RNA miR-21,
which targets the 3′ untranslated region of Pdcd4mRNA [9–11]. On the
protein level, Pdcd4 can be down-regulated by S6K-mediated phosphor-
ylation which triggers its ubiquitination and subsequent degradation via
the E3 ubiquitin ligase complex SCF(betaTRCP) [12,13]. Decreased
expression of Pdcd4 contributes to tumor development in different
ways: Several studies have shown that decreased Pdcd4 expression
increases the mobility and invasiveness of tumor cells [8,11,14,15]. In+49 251 83 33206.
pnauer).addition, decreased Pdcd4 expression has been shown to impair the
cellular DNA-damage response [16–19].
Pdcd4 encodes a highly conserved, predominantly nuclear/cytoplasmic
phosphoprotein [20,21] whose subcellular localization is controlled by
protein kinase Akt-mediated phosphorylation [21]. Pdcd4 contains two
so-called MA-3 domains located in the central and the C-terminal parts
of the protein, and an N-terminal RNA-binding domain. Twomain activi-
ties have been attributed to Pdcd4. Several studies have shown that Pdcd4
modulates the transcription of speciﬁc genes by affecting the activities of
certain transcription factors, such as c-Jun [22,23], Sp1 [15], Twist1 [24]
and p53 [16,19]. In addition, Pdcd4 acts as a translation suppressor.
Pdcd4 interacts via its MA-3 domains with the eukaryotic translation ini-
tiation factor eIF4Aand inhibits its RNAhelicase activity,which is required
for unwinding secondary structures in 5′-untranslated regions (UTRs) of
mRNAs [25–31]. It is therefore thought that Pdcd4 suppresses the transla-
tion of mRNAs containing 5′ structured UTRs. This has been conﬁrmed
using artiﬁcial RNAs with stable hairpin structures in their 5′-UTRs
[25,26] and by the identiﬁcation of p53 mRNA as a physiological
Pdcd4 targetmRNA [18]. Recently, a furthermechanism of translational
suppression by Pdcd4 has been identiﬁed which involves direct RNA-
binding of Pdcd4 to target mRNAs [32,33].
Here, we have investigated the inﬂuence of Pdcd4 on the expression
of protein kinase Hipk2. Hipk2 is a highly conserved protein kinase that
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response to DNA damage [34–36]. We have previously shown that
Pdcd4 interferes with the phosphorylation of p53 by Hipk2 [19]. During
this work we observed that Pdcd4 also inhibits the expression of Hipk2.
We have now explored the effect of Pdcd4 on Hipk2 expression inmore
detail. We show that Pdcd4 reduces Hipk2 expression by interfering
with an auto-regulatory feedback mechanism, by which Hipk2 stimu-
lates the translation of its own mRNA. Our data reveal a novel function
of Pdcd4 and provide the ﬁrst evidence for translational control of
Hipk2 expression.
2. Materials and methods
2.1. Cells
Human Hela, HEK293 and HepG2 cells, quail QT6 cells and chicken
DF-1 cells were grown in Iscove's modiﬁed DMEM supplemented with
10% fetal calf serum. Proteasome inhibitor MG132 and caspase inhibitor
z-VAD-FMK were used at 10 and 20 μM, respectively. Cycloheximide
was used at a ﬁnal concentration of 50 μg/ml.
2.2. Expression vectors and transfections
Expression vectors for HA-tagged Hipk2 (pLNCX-HA-Hipk2-wt) and
a HA-tagged kinase-dead mutant of Hipk2, carrying a K221A mutation
(pLNCX-HA-Hipk2-KD), were obtained from T. Hofmann [37]. Hipk2
deletion constructs Hipk2-ΔN170, Hipk2(1–170) and Hipk2(70–220)
have been described [38]. Expression vectors for Flag-tagged Hipk1
and a kinase-dead mutant (Hipk1-K219A) have been described [39]
and were subcloned into pCDNA3. The expression vectors for chicken
andhuman Pdcd4have been described [20,40]. The following expression
vectors for mutant versions of human Pdcd4 were used: pCDNA4-
hPdcd4-ΔRBD and pCDNA4-hPdcd4-RBM1+2 encode RNA-binding
deﬁcient Pdcd4 proteins lacking amino acids 16 to 150 or harboring
several amino acid substitutions in the RNA-binding domain, respec-
tively. Both mutants have been described before [32,40]. pCDNA4-
hPdcd4-mut4 encodes an eIF4A binding-deﬁcient mutant of human
Pdcd4 in which Glu-249, Asp-253, Asp-414, and Asp-418were changed
to Ala [18]. pCDNA4-hPdcd4-RDBstop, pCDNA4-hPdcd4-stop300 and
pCDNA4-hPdcd4-stop435 encode human Pdcd4 deleted after amino
acids 154, 300 and 435 and were generated by introducing stop codons
at the corresponding positions in the coding sequence. Transient
transfection of plasmid DNAs into QT6 or Hela cells was performed by
calcium phosphate co-precipitation, as described [16].
2.3. CRISPR/Cas9 mediated silencing of Pdcd4
The CRISPR/Cas9 expression vector pSpCas9n(BB)-2A-puro [41],
which encodes a mutated “nickase” version of Cas9 and contains a
cloning site for a guide RNA, was obtained from Addgene. Guide-RNA
target sequences were selected as described [42]. We generated
two plasmids targeting the sequences CCTTAGTCGCCTTTTTGCCTTGG
(Pdcd4 antisense strand) and GGCGATTCGGTCAGCGACAGTGG (Pdcd4
sense strand) and transfected them simultaneously into HEK293 cells
using Metafectene™ (Biontex, Munich, Germany). No off-targets are
predicted for this pair of guide-RNAs. Transfectants were enriched by
puromycin selection and individual clones were analyzed by western
blotting for Pdcd4 expression. Two independent Pdcd4-deﬁcient clones,
referred to as K4 and K13, were used for further analysis.
2.4. Northern blotting
Polyadenylated RNA was prepared from transfected cells as
described before [16]. Hipk1, Hipk2, GFP and ribosomal protein S17
mRNAs were detected using 32P-radiolabeled probes derived from the
corresponding cDNA clones.2.5. Pulse-labeling with 35S-methionine and immunoprecipitation
Cells transfected with the desired expression vectors were la-
beled with 35S-methionine (Hartmann Analytics, N800 Ci/mmol) in
methionine-free medium at 100 μCi/ml for the desired times. The cells
were then lysed in RIPA buffer (50 mM Tris–HCl, pH 7.4; 150 mM
NaCl; 1 mM EDTA; 0.5% NP-40; 0.5% sodium desoxycholate; 0.1%
SDS). After incubation on ice for 30 min, lysates were centrifuged at
14,000 ×g for 30 min and the supernatant was immunoprecipitated
with the appropriate antibodies for 1 to 2 h at 4 °C. Protein-A Sepharose
beads were then added and incubated further for 3 h at 4 °C under con-
stant agitation. Immune complexes bound to the beads were collected
by centrifugation, washed ﬁve times with RIPA buffer, once with PBS
and bound proteinswere visualized by SDS-PAGE and autoradiography.
2.6. Antibodies
Pdcd4 was detected by a rabbit antiserum raised against the
aminoterminus of human Hipk2 [16]. Antibodies against Hipk2 were
kindly provided by Lienhard Schmitz. Anti-HA, anti-Flag and anti-Myc
antibodies were obtained from commercial suppliers.
3. Results
3.1. Pdcd4 suppresses the translation of Hipk2 mRNA
In a recent study on the effect of Pdcd4 on Hipk2-dependent
phosphorylation of p53 we noted that the expression of Hipk2 in cells
transfected with a Hipk2 expression vector was reduced when Pdcd4
was co-expressed [19]. To conﬁrm this initial observation we co-
transfected expression vectors for Hipk2 and Pdcd4 and analyzed the
amounts of both proteins by western blotting (Fig. 1A). Increasing
concentrations of Pdcd4 decreased the amount of Hipk2 expressed
froma constant amount of Hipk2 expression vectorwhereas the expres-
sion of an unrelated protein, YFP, was not affected by Pdcd4 (bottom
panel of Fig. 1A), arguing against an unspeciﬁc effect of Pdcd4. Similar
co-transfections performed in different cell lines demonstrated that
the suppressive effect of Pdcd4 was not cell line speciﬁc (Fig. 1B). Fur-
thermore, co-transfection of an expression vector for chicken instead
of human Pdcd4 (Fig. 1C) also decreased Hipk2 expression, indicating
that the ability to inhibit Hipk2 expression is conserved between
human and chicken Pdcd4.
To demonstrate that Pdcd4 also inhibits the expression of endoge-
nous Hipk2 in un-transfected cells we generated Pdcd4-deﬁcient
subclones of the HEK293 cell line by CRISPR (clustered regulatory
interspaced palindromic repeat)/Cas9-induced genome engineering.
Previous work has shown that human codon-optimized Cas9 nuclease
can be targeted by a guide-RNA to speciﬁc sites in the human genome
to induce cleavage at the desired locus [41,43]. We constructed two
targeting vectors encoding the “nickase” mutant of human codon-
optimized Cas9 and single guide RNAs targeting the human Pdcd4
gene. Independent clones of HEK293 cells transfected simultaneously
with both constructs were then selected and tested bywestern blotting
for Pdcd4 expression. We then analyzed the expression of Hipk2 in
wild-type HEK293 cells and two of the obtained Pdcd4-deﬁcient
subclones. As shown in Fig. 1D both Pdcd4-deﬁcient clones expressed
higher levels of Hipk2 than the wild-type cells. This demonstrated that
loss of Pdcd4 expression leads to higher Hipk2 expression, consistent
with the notion that Pdcd4 suppresses Hipk2 expression also when
expressed at the endogenous level.
To ﬁnd out how Pdcd4 suppresses Hipk2 expressionwe ﬁrst investi-
gated whether Pdcd4 decreases the level of Hipk2 mRNA transcribed
from the Hipk2 expression vector. However, this was not the case
(Fig. 2A). This suggested that Pdcd4 either promotes the degradation
of Hipk2 or suppresses its synthesis. To distinguish between these
possibilities we ﬁrst investigated the inﬂuence of proteasome (MG132)
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Fig. 1. Inhibition of Hipk2 expression by Pdcd4. A. QT6 ﬁbroblasts were transfected with the indicated combinations of plasmids encoding human Hipk2, YFP and human Pdcd4 together
with the β-galactosidase plasmid pCMVβ to monitor transfection efﬁciencies. 24 h later β-galactosidase-normalized amounts of total protein extracts were analyzed by western blotting
with antibodies against the HA-tag, Pdcd4 and GFP. B. Hela cells and chicken DF-1 cells were transfected with expression vector for HA-Hipk2 and human Pdcd4. Cells were analyzed as
described in A. C. QT6 cells were transfectedwith expression vectors for HA-tagged human Hipk2 and chicken Pdcd4 and analyzed as above. D.Western blot analysis of wild-type HEK293
cells (wt) and two Pdcd4-negative HEK293 subclones (K4 and K13) generated by CRISPR/Cas9-mediated genome editing.
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expression by Pdcd4. If Pdcd4 promotes the degradation of Hipk2we ex-
pected the inhibitory effect of Pdcd4 to be abrogated by these inhibitors.
Although the amount of Hipk2 was increased by MG132 the ability of
Pdcd4 to suppress Hipk2 expression was not affected by MG132 or the
caspase inhibitor (Fig. 2B). It therefore appeared unlikely that Pdcd4
suppresses Hipk2 expression by promoting its degradation. To conﬁrm
this we compared the half-life of Hipk2 in the absence and presence of
Pdcd4. Cells expressingHipk2 alone or togetherwith Pdcd4were treated
with cycloheximide to block de novo protein synthesis. The cells were
then cultivated further in the presence of cycloheximide and the amount
of Hipk2 remaining after different times was analyzed by western
blotting. Consistent with the previous experiments the amount of
Hipk2 was signiﬁcantly higher in the absence than in the presence of
Pdcd4, however, the decrease of Hipk2 over time was very similar in
both cases (Fig. 2C). We estimate the half-life of Hipk2 to be approxi-
mately 2 h in the presence or absence of Pdcd4. Finally, we performed
a metabolic labeling experiment in which cells transfected with Hipk2
or Hipk2 plus Pdcd4 expression vectors were labeled for 20 min with
radioactive methionine, harvested immediately and analyzed by immu-
noprecipitation. Because the labeling period is relatively short compared
to the estimated half-life of the protein, the amount of labeled protein is
primarily dependent on the rate of its synthesis. The fact that signiﬁcant-
ly more labeled Hipk2 was synthesized in the absence of Pdcd4 than in
its presence directly demonstrated that Pdcd4 suppresses the translation
of Hipk2 mRNA.3.2. Suppression of Hipk2 expression by Pdcd4 requires the N-terminal
domain of Pdcd4 but is independent of the ability of Pdcd4 to interact with
RNA or eIF4A
Previous work has implicated the ability of Pdcd4 to interact with
eIF4A aswell as its RNA binding activity in the translational suppression
of speciﬁc mRNAs [18,25,26,32,33]. To investigate which of these activ-
ities, if any, are required for the suppression of Hipk2 expression we
examined the inhibitory activity of several Pdcd4 mutants. Fig. 3 shows
that a truncated form of Pdcd4 containing only the RNA-binding domain
was able to suppress Hipk2 expression whereas the C-terminal part of
Pdcd4 without the RNA binding domain was barely active. This demon-
strated that the MA-3 domains and the ability of Pdcd4 to interact with
the translation initiation factor eIF4A are not involved in the suppression
of Hipk2 expression. To ﬁnd out whether the RNA-binding activity of
Pdcd4 is required for suppression of Hipk2 expression we used a Pdcd4
mutant that lacks RNA-binding activity. In this mutant several arginine
and lysine residues that are essential for the RNA-binding activity of
Pdcd4 have been replaced by alanine [40]. The experiment showed
that the RNA-binding defective mutant still inhibited Hipk2 expression
(Fig. 3). This indicated that the RNA-binding activity of Pdcd4 is not
required for the suppression of Hipk2 expression. Fig. 3 also shows that
a Pdcd4 protein carrying mutations in the MA-3 domains that abolish
the binding of eIF4A was also able to suppress Hipk2 expression,
conﬁrming that the suppressive effect of Pdcd4 is not mediated by
interaction with eIF4A. We also performed RNA-immunoprecipitation
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Fig. 2.Pdcd4 suppresses translation ofHipk2mRNA.A.QT6 cellswere transfectedwith expression vectors forHA-Hipk2 andPdcd4. Cellswere harvested after 24 h and analyzed for protein
and RNA expression. Top andmiddle panel: Aliquots of the cells were analyzed bywestern blotting with antibodies against the HA-tag and Pdcd4. Bottom panel: Northern blot analysis of
RNA isolated from the transfected cells. B. QT6 cells were transfected as indicated at the bottom. 24 h later the cells and treated with 10 μM of the proteasome inhibitor MG132 for 4 h or
with the caspase inhibitor z-VAD-FMK (20 μM) for 4 h or incubatedwithout inhibitor. Total cell extracts were then analyzed bywestern blottingwith antibodies against Hipk2 and Pdcd4.
Themiddle panel depicts a shorter exposure of the upper panel to show that the Pdcd4-induced inhibition of Hipk2 is virtually identical in the presence or absence ofMG132. C. QT6 cells
were transfectedwith expression vectors for HA-Hipk2 and Pdcd4. 24 h after transfection 50 μg/ml cycloheximide was added to the growth medium and the cells were harvested imme-
diately or after further incubation, as indicated at the top. Total cell extracts were analyzed bywestern blotting with anti-HA antibodies (Top andmiddle panels) or Pdcd4 antibodies (bot-
tom panel). The middle panel shows a shorter exposure of the top panel. Untransfected cells are marked as control. D. QT6 cells were transfected as in C. 24 h after transfection the cells
were labeled for 20minwith 35S-methionine, lysed and immunoprecipitatedwith antiserum against the HA-tag, followed by SDS-PAGE and autoradiography.Molecular weightmarkers
are indicated in kilodaltons.
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these experiments failed to provide evidence that Pdcd4 is bound
to Hipk2 mRNA (data not shown), suggesting that Pdcd4 suppresses
translation of Hipk2 mRNA by a novel mechanism.
3.3. Hipk2 stimulates translation of its own mRNA
During this work we observed that a full-length kinase-dead
construct of Hipk2 containing only a single amino acid replacement
(K221A) was expressed at signiﬁcantly lower levels than the
corresponding wild-type construct, although the same amounts of
expression vector were transfected. In addition, the wild-type kinase
had a higher apparent molecular weight than the kinase-dead mutant
(Fig. 4A). Work from several groups has shown that Hipk2 is able to
phosphorylate itself to give rise to a form with slower electrophoretic
mobility in SDS-polyacrylamide gels [37,44–47]. Northern blot analysis
of cells transfected with wild-type or kinase-dead Hipk2 expression
vectors showed that the difference in the expression of both proteins
was not due to differential transcription (Fig. 4B). Because phosphoryla-
tion might affect the stability of the protein we wondered whether the
different expression levels of wild-type and kinase-dead Hipk2 were
due to a difference of the half-life between the wild-type and the mu-
tant protein. To address this possibility, we compared the expression
levels of wild-type and mutant Hipk2 in the absence and presence ofthe proteasome inhibitor MG132. We reasoned that if the mutant
protein was less stable than the wild-type protein, inhibition of
proteasomal degradation would cause the expression levels of both
proteins to become more similar or identical. Fig. 4C shows that both
proteins were still expressed at very different levels even when
degradation was inhibited. In addition, we measured the half-life of
wild-type and kinase-dead Hipk2 by treating cells transfected with
expression vectors for both forms of Hipk2 with cycloheximide and fol-
lowing the degradation of both proteins over several hours (Fig. 4D).
Both proteins showed a very similar decrease over time. Finally, we
also performed a pulse-labeling experiment of cells transfected with
equal amounts of expression vectors for wild-type and kinase-dead
Hipk2. The cells were labeled with radioactive methionine for 30 min,
harvested immediately and analyzed by immunoprecipitation with
antibodies against the HA-tag (Fig. 4E). Since the labeling period was
short compared to the estimated half-life of the protein the difference
of the amounts of labeled proteins reﬂects primarily the difference in
the rate of their synthesis. Taken together, these experiments showed
that the differential expression of wild-type and kinase-dead Hipk2
was not due to differential stability of both proteins but to a higher
rate of synthesis of the wild-type protein. Since the RNA amounts for
both proteins were not different, we concluded that the mRNA for
wild-type Hipk2 is translated more efﬁciently than the RNA for the
kinase-dead mutant.
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efﬁciencies of both RNAs we thought it unlikely that replacement of
one amino acid and the corresponding difference in the nucleotide se-
quence between both RNAs could explain the difference in translation
efﬁciency. We therefore considered the possibility that wild-type
Hipk2, but not the kinase-dead mutant, stimulates translation of its
own mRNA by a feed-back mechanism. If such a mechanism existed
onemight expect that kinase-active Hipk2would stimulate the transla-
tion of mRNA encoding kinase-dead Hipk2 by a “trans-stimulatory”
mechanism. To test this idea we co-expressed kinase-dead Hipk2 with
or without active but truncated forms of Hipk2 and analyzed protein
as well as mRNA levels (Fig. 5A). This experiment showed that the
presence of the active Hipk2/1-541 or Hipk2/1-860 caused a signiﬁcant
increase of the expression of the kinase-dead Hipk2 although the
amount of the mRNA encoding the kinase-dead Hipk2 remained the
same. This demonstrated that active forms of Hipk2 are able to stimu-
late the translation of Hipk2 RNA. When the kinase-dead instead of
the kinase-active form of truncated Hipk2/1-860 was used, no stimula-
tion of the expression of the full-length kinase-dead Hipk2 occurred
(Fig. 5B), demonstrating that the kinase activity plays a crucial role in
increasing the translation of Hipk2 RNA.We also observed a large differ-
ence in the expression levels of the kinase-active and kinase-dead
versions of the truncated Hipk2/1-860 construct, most likely because
the kinase-active construct stimulates its own expression. Taken
together, these observations indicated that Hipk2 stimulates the trans-
lation of its own mRNA by a mechanism that depends on its kinase
activity.
We wondered whether the stimulation of the translation of Hipk2
mRNA by Hipk2 is a peculiarity of the QT6 ﬁbroblast line used in most
of the experiments described so far, or whether it also occurs in otherHipk2-KD
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active Hipk2 constructs, as indicated. Cells were analyzed 24 h after transfection for Hipk2
cells was analyzed by northern blotting with Hipk2-speciﬁc probe (bottom panel). B. QT6 cells
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GFP (top, middle and bottom panels, respectively).cells, particularly in human cells. We therefore transfected Hela cells
with equivalent amounts of expression vectors for wild-type and
kinase-dead Hipk2 and analyzed the resulting amounts of Hipk2 by
western blotting. Fig. 5C shows that the expression of the wild-type ki-
nase was signiﬁcantly higher than the expression of the kinase-dead
mutant, suggesting that wild-type Hipk2 stimulates its expression also
in human cells. To further support this conclusion we transfected Hela
cells with expression vectors for Myc-tagged full-length kinase-dead
Hipk2 and the HA-tagged truncated form of the active kinase
(Fig. 5D). This experiment showed that the amount of the kinase-dead
mutant was strongly increased by the active kinase, conﬁrming that
Hipk2 stimulates translation of its own mRNA also in human cells.3.4. Pdcd4 interferes with the auto-stimulation of Hipk2 translation
Since our data showed that Pdcd4 suppresses the translation of
Hipk2mRNAwewere interested to knowwhether or not this inhibitory
function of Pdcd4 is related to the auto-stimulation of Hipk2 translation.
If the inhibitory activity of Pdcd4 was unrelated to the auto-stimulation
of Hipk2 expression, Pdcd4 is expected to suppress the expression of
wild-type and kinase-dead Hipk2 to similar extent. If, on the other
hand, Pdcd4 speciﬁcally interferes with the auto-stimulation of Hipk2
expression, Pdcd4 should have a much stronger effect on wild-type
than on kinase-deadHipk2 expression. Fig. 6A shows that the expression
of kinase-dead Hipk2 was only slightly affected by Pdcd4 while wild-
type Hipk2 was strongly inhibited under the same conditions. This
indicated that Pdcd4 does not suppress translation of Hipk2 mRNA per
se but that it speciﬁcally interferes with the auto-stimulatory function
of Hipk2, as depicted schematically in Fig. 6B.+ + +
- + +
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Finally, we wondered if the cooperation of Hipk2 and Pdcd4 would
affect only the expression of Hipk2 or if heterologous RNAs might also
be regulated in similar manner by both proteins. As a ﬁrst step, weA
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feed-back mechanism as Hipk2. Furthermore, Pdcd4 suppressed the
expression of the active form of Hipk1 but not that of the kinase-dead
mutant. As in the case of Hipk2, the decrease of Hipk1 expression by
Pdcd4 was not accompanied by a decrease of the Hipk1 mRNA levels
(Fig. 7B). The difference in the expression levels of wild-type and
kinase-deadHipk1 suggested that Hipk1, likeHipk2,might also regulate
its translation by an autoregulatory mechanism. To test this, we co-
transfected expression vectors for full-length kinase-dead Hipk1
and an active but C-terminally truncated form of Hipk1. Fig. 7C shows
that the amount of the kinase-dead Hipk1 was strongly increased by
co-expression of active Hipk1 without concurrent increase of the
mRNA level of kinase-dead Hipk1. This suggested that Hipk1, like
Hipk2 stimulates translation of its own mRNA. Finally, we were inter-
ested to know if the kinases stimulate only the translation of their
own RNAs or if they can “cross-stimulate” each other. As shown in
Fig. 7D, co-expression with an active form of Hipk2 strongly increased
the expression of the kinase-dead form of Hipk1, demonstrating that
Hipk2 also stimulates the translation of Hipk1 RNA.
4. Discussion
Our work reveals an unexpected and novel link between Pdcd4 and
the expression of the protein kinase Hipk2 and thereby provides new
insight into the role of Pdcd4 as a translation suppressor as well as
into the control of Hipk2 expression.Hipk2 is an evolutionary conserved
protein kinase which plays important roles in different biological
processes ranging from the response to DNA damage and oxidative
stress to hypoxia signaling and the control of apoptosis, proliferation
and differentiation [48,49]. This multitude of important functions
requires precise control of Hipk2 activity to prevent dysregulation of
these processes and the development of diseases, such as cancer. Unlike
many other protein kinases Hipk2 appears not to require activating
events after its synthesis, such as the phosphorylation by an “upstream
activating kinase”. Rather, Hipk2 activates itself by autophosphorylation
during its synthesis and appears to be regulated by themodulation of its
stability [37,44–47]. Recent studies have revealed a complex network
of Hipk2 interacting proteins that control the ubiquitin-dependent
degradation of Hipk2. The function of this regulatory network has
been explored in detail in the response to DNA-damage and hypoxia
[48–51]. Under normal conditions the amount of Hipk2 is low due to
its interaction with several E3 ubiquitin ligases, including Siah1 and 2,
WSB-1 and Fbx3, which mediate the ubiquitination and subsequent
degradation of Hipk2. Following stress (e.g. DNA damage) Hipk2 is
released from the ubiquitin ligases, which leads to its stabilization and
increased phosphorylation of its downstream targets.
The work presented here adds a completely new aspect to the
picture of Hipk2 regulation by providing the ﬁrst evidence that the ex-
pression of Hipk2 is also controlled on the level of translation of Hipk2
mRNA. Our work demonstrates that Hipk2 controls an autoregulatory
feed-back loop by which it stimulates its own synthesis. The fact that
the kinase-dead Hipk2 mutant was not able to increase its translation,
indicates that this feed-back stimulation requires the kinase activity of
Hipk2 and suggests that the phosphorylation of an unknown down-
stream target of Hipk2 is responsible for the increased translation of
Hipk2 mRNA. Our initial analysis of the expression of Hipk1 has
shown that translation of Hipk1 is regulated by a similar feed-back
mechanism as that of Hipk2. Moreover, we have shown that the expres-
sion of kinase-dead Hipk1 is also stimulated by Hipk2. This raises the
interesting possibility that Hipk2 stimulates not only the translation of
its own but also of other mRNAs, as exempliﬁed by Hipk1 mRNA. It
will therefore be interesting to investigate the mechanistic basis of
this new function of Hipk2 and to search for mRNAs whose translation
is affected by Hipk2.
A second conclusion of our work is that Pdcd4 affects Hipk2
expression by interfering with the autostimulation of Hipk2 mRNAtranslation. This indicates that the Hipk2-dependent feedback loop
is not constitutively active, but that it is controlled by Pdcd4 and per-
haps other factors. Pdcd4 itself is also regulated in a complex man-
ner, including phosphorylation of Pdcd4 by S6- and Akt-kinases
and silencing of Pdcd4 expression by microRNA-21 [9–11]. Thus,
in addition to the control of Hipk2 stability there appears to be an
additional complex layer of regulation of Hipk2 expression that
acts on the level of translation.
Our work also provides new insight into the function of Pdcd4 as a
translation suppressor. Because Pdcd4 interacts with the translation
initiation factor eIF4A and inhibits its helicase activity, it was initially
proposed that Pdcd4 suppresses the translation of mRNAs containing
structured 5′-UTRs in an eIF4A-dependent manner [25,26]. It now
appears that the role of Pdcd4 as translation suppressor is more
complex. Our data show that Pdcd4 is involved in translational suppres-
sion of Hipk2 mRNA by a mechanism that is not dependent on the
Pdcd4-eIF4A interaction. Our work shows that the suppression of
Hipk2 expression is dependent on the N-terminal domain of Pdcd4.
This part of Pdcd4 is involved in protein–protein-interactions, for exam-
ple with Daxx, PRMT5 and the poly(A)-binding protein [19,52,53], but
also functions as an RNA-binding domain [32,41]. We have recently
shown that Pdcd4 suppresses the translation of c-myb and A-myb
mRNAs by directly binding to the RNA [32,33]. Direct Pdcd4-RNA
binding seems not to be involved in the case of Hipk2 mRNA because
a RNA-binding defective Pdcd4 mutant was still able to suppress
Hipk2 translation. How Pdcd4 acts mechanistically to inhibit the
Hipk2-dependent feed-back stimulation of its own synthesis is not
clear at present. A possible scenario is that Pdcd4 modiﬁes the expres-
sion or activity of a downstream effector, e.g. a RNA-binding protein or
regulatory RNA that interacts with Hipk2 RNA to affect its translation.
In any case, our work adds a novel aspect to the current picture of
mechanisms by which Pdcd4 affects the translation of cellular mRNAs.
As Hipk2 plays important roles in numerous important biological
processes, Pdcd4 is likely to exert pleiotropic effects on these processes
and thereby inﬂuences cellular homeostasis by multiple mechanisms.
Hipk2 has recently been shown to phosphorylate the cyclin-dependent
kinase inhibitor p27(Kip1) at Ser10, leading to the stabilization of
p27(Kip1) and increased cell motility [54]. A decrease of Pdcd4, as
observed in many tumor cells, might therefore stimulate cell motility
via increased expression of Hipk2 and subsequent phosphorylation of
p27(Kip1). This is consistent with several studies that have shown
that siRNA-mediated knock-down of Pdcd4 leads to increased cell
motility [8,11,14,15]. Although Hipk2 is considered to be itself a tumor
suppressor [36] there is also evidence for a pro-oncogenic role of
Hipk2 in certain tumors, such as brain tumors and cervical carcinomas
[55–57], where Hipk2 is frequently overexpressed. Pdcd4 is down-
regulated in invasive cervical cancer [58] suggesting that it may
counteract Hipk2 in this type of cancer. It is also possible that the effect
of Pdcd4 on Hipk2 expression is not directly related to Pdcd4's role as a
tumor suppressor. As pointed out, Hipk2 plays a prominent role in the
DNA damage response by phosphorylating p53 at Ser46 [37,44]. We
have previously reported that Pdcd4 suppresses the phosphorylation
of p53 at Ser46 as well as the translation of p53 mRNA in cells growing
under normal conditions [18,19]. That Pdcd4 also suppresses Hipk2
expression accords with these observations and supports a model in
which Pdcd4 plays a role as a dampening factor that ensures a low
level of activity of the Hipk2-p53 axis in unstressed cells. In any case,
the identiﬁcation of the Hipk2-dependent auto-stimulation and the
disruption of this mechanism by Pdcd4 open up new perspectives for
future studies on the function of Pdcd4 and Hipk2.Transparency document
The Transparency document associated with this article can be
found, in the online version.
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